55 related articles for article (PubMed ID: 10949987)
1. A pilot study of low dose hydroxyurea as a novel resistance modulator in metastatic renal cell cancer.
Hao D; Huan SD; Stewart DJ; Segal RJ; Yau JC
J Chemother; 2000 Aug; 12(4):360-6. PubMed ID: 10949987
[TBL] [Abstract][Full Text] [Related]
2. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea did not enhance the clinical response to vinblastine in patients with anthracycline-resistant metastatic breast cancer.
Huan SD; Yau JC; Tomiak E; Goel R; Cripps C; Gertler SZ; Prosser IA; Stewart DJ
Tumori; 1996; 82(6):576-8. PubMed ID: 9061067
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
[TBL] [Abstract][Full Text] [Related]
5. Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate.
Katakkar SB; Franks CR
Cancer Treat Rep; 1978 Sep; 62(9):1379-80. PubMed ID: 688282
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Motzer RJ; Lyn P; Fischer P; Lianes P; Ngo RL; Cordon-Cardo C; O'Brien JP
J Clin Oncol; 1995 Aug; 13(8):1958-65. PubMed ID: 7636536
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.
Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL
Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
9. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR
Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study.
Agarwala SS; Bahnson RR; Wilson JW; Szumowski J; Ernstoff MS
Am J Clin Oncol; 1995 Jun; 18(3):211-5. PubMed ID: 7747708
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.
Berlin J; King AC; Tutsch K; Findlay JW; Kohler P; Collier M; Clendeninn NJ; Wilding G
Invest New Drugs; 1994; 12(2):137-41. PubMed ID: 7860231
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma.
Trump DL; Ravdin PM; Borden EC; Magers CF; Whisnant JK
J Biol Response Mod; 1990 Feb; 9(1):108-11. PubMed ID: 2319258
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the loss of multiple drug resistance by hydroxyurea.
Christen RD; Shalinsky DR; Howell SB
Semin Oncol; 1992 Jun; 19(3 Suppl 9):94-100. PubMed ID: 1641661
[TBL] [Abstract][Full Text] [Related]
15. Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas.
Raymond E; Faivre S; Weiss G; McGill J; Davidson K; Izbicka E; Kuhn JG; Allred C; Clark GM; Von Hoff DD
Clin Cancer Res; 2001 May; 7(5):1171-80. PubMed ID: 11350881
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma.
Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
Cancer Chemother Pharmacol; 1998; 42(5):415-7. PubMed ID: 9771957
[TBL] [Abstract][Full Text] [Related]
17. Vinblastine and erythromycin: an unrecognized serious drug interaction.
Tobe SW; Siu LL; Jamal SA; Skorecki KL; Murphy GF; Warner E
Cancer Chemother Pharmacol; 1995; 35(3):188-90. PubMed ID: 7805175
[TBL] [Abstract][Full Text] [Related]
18. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
19. Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line.
Duensing S; Brevis Nunez F; Meyer N; Anastassiou G; Nasarek A; Grosse J; Buer J; Probst M; Ganser A; Alzpodien J
Invasion Metastasis; 1996; 16(2):65-72. PubMed ID: 9030241
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
